Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Total Debt (2016 - 2025)

Historic Total Debt for Ligand Pharmaceuticals (LGND) over the last 12 years, with Q3 2025 value amounting to $445.5 million.

Ligand Pharmaceuticals' Total Debt changed N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A changed from last year.
Latest data reveals that Ligand Pharmaceuticals reported Total Debt of $445.5 million as of Q3 2025.
Ligand Pharmaceuticals' Total Debt's 5-year high stood at $445.5 million during Q3 2025, with a 5-year trough of $76.6 million in Q3 2022.
Its 3-year average for Total Debt is $158.1 million, with a median of $76.8 million in 2023.